SCHEMBL3910779

SCHEMBL3910779

N#Cc1cc(CO)ccc1-c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 3/20 0.56
ESR2 Q92731 1/20 0.44
XDH P47989 2/20 0.43
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
CHKA P35790 1/20 0.42
GRM5 P41594 1/20 0.41
CNR1 P21554 1/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
GALR3 O60755 1/20 0.41
GAA P10253 1/20 0.41
TSHR P16473 1/20 0.40
MCL1 Q07820 1/20 0.40
WNT3A P56704 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4610873 0.86 CYP19A1 (0.53) CYP19A1ESR2XDHMAOAMAOB
SCHEMBL7572092 0.86 CYP19A1 (0.56) CYP19A1ESR2MAOAMAOBKDM4E
SCHEMBL29170969 0.84 CYP19A1 (0.55) CYP19A1ESR2XDHMAOAMAOB
SCHEMBL31022184 0.84 CYP19A1 (0.55) CYP19A1XDHCHKAGRM5CNR1
SCHEMBL27331545 0.84 CYP19A1 (0.55) CYP19A1ESR2XDHMAOAMAOB
SCHEMBL9377731 0.84 CSNK2A1 (0.57) CYP19A1ESR2XDHCHKACNR1
SCHEMBL1838707 0.84 CYP19A1 (0.55) CYP19A1ESR2XDHMAOAMAOB
SCHEMBL3902369 0.84 CYP19A1 (0.55) CYP19A1ESR2XDHMAOAMAOB
SCHEMBL19567997 0.84 CYP19A1 (0.55) CYP19A1XDHCHKAGRM5CNR1
Hydrochloric Acid SCHEMBL500699 0.83 CSNK2A1 (0.58) CYP19A1ESR2XDHCHKACNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090324581-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE DAIICHI SANKYO COMPANY LIMITED (JP) 2009-12-31 US disclosed
US-20090324581-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE DAIICHI SANKYO COMPANY LIMITED (JP) 2009-12-31 US disclosed
US-20090324581-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE DAIICHI SANKYO COMPANY LIMITED (JP) 2009-12-31 US disclosed
EP-2017263-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2009-01-21 EP disclosed
CN-1680335-A Preparation of olmesartan medoxomill WANSHENG PHARMACEUTICAL CO LTD (CN) 2005-10-12 CN disclosed
CN-1510035-A Preparation of Aomeishatan 北京双鹤药业股份有限公司 2004-07-07 CN disclosed
US-6077853-A Inhibitors of farnesyl-protein transferase MERCK & CO., INC. (US) 2000-06-20 US disclosed
EP-0951285-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE Merck & Co., Inc. (US) 1999-10-27 EP disclosed
US-5939439-A Inhibitors of farnesyl-protein transferase MERCK & CO., INC. (US) 1999-08-17 US disclosed
WO-1998029119-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1998-07-09 WO disclosed
EP-0654030-A1 IMIDAZOLE DERIVATIVES HAVING A II ANTAGONIST ACTIVITY. LUSO FARMACO INST (IT) 1995-05-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090324581-A1 HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE S1PR3, S1PR2, S1PR1 CYP19A1 2185/4885ESR2 1862/4885XDH 3610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.